Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, PR, Brazil.
Department of Medicine, Regional University Hospital of Maringá, PR, Brazil.
Complement Ther Med. 2021 Dec;63:102781. doi: 10.1016/j.ctim.2021.102781. Epub 2021 Oct 7.
To investigate evidence for the treatment of childhood colic by supplementing Lactobacillus reuteri in infants breastfed with breast milk.
The study was conducted according to the PRISMA protocol. The databases used for acquiring data were PubMed and Web of Science, applying MeSH terms and free terms. Meta-analysis was conducted using Stata ™ 12.0. The risk of bias was evaluated by the Review Manager (RevMan) 5.3 tool, and the strength of evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Ten clinical trials were included in the review. The administration of L. reuteri (DSM 17938 or ATCC55730) was tested in infants (n = 248) versus the control/placebo group (n = 229). Eight articles were included in the meta-analysis. There was a significant response in reducing crying time (minutes/day) and treatment effectiveness (reduction ≥ 50% in average daily crying time) in the first week (p = 0.001 and p = 0.003, respectively). These results were similar in the second, third weeks (p < 0.001 for both outcomes) and fourth weeks (p<0.001 and p = 0.002, respectively). The risk of bias was low for the majority of the studies. Confidence in evidence was considered very low for crying time and low for effectiveness treatment.
The evidence shows that the administration of Lactobacillus reuteri to babies fed with breast milk reduces the crying time in babies diagnosed with colic. But our confidence in the effect estimate is limited.
研究在母乳喂养的婴儿中补充罗伊氏乳杆菌(Lactobacillus reuteri)治疗儿童绞痛的证据。
本研究按照 PRISMA 方案进行。用于获取数据的数据库是 PubMed 和 Web of Science,应用了 MeSH 术语和自由术语。使用 Stata ™ 12.0 进行荟萃分析。使用 Review Manager(RevMan)5.3 工具评估偏倚风险,并使用推荐评估、制定与评价分级(Grading of Recommendations Assessment, Development and Evaluation,GRADE)评估证据强度。
综述纳入了 10 项临床试验。在婴儿(n=248)中测试了罗伊氏乳杆菌(DSM 17938 或 ATCC55730)的给药与对照组/安慰剂组(n=229)的比较。8 篇文章纳入了荟萃分析。在第一周内,减少哭泣时间(分钟/天)和治疗效果(平均每日哭泣时间减少≥50%)有显著反应(p=0.001 和 p=0.003)。在第二、第三周(两个结局均 p<0.001)和第四周(p<0.001 和 p=0.002)也有类似结果。大多数研究的偏倚风险较低。对哭泣时间和治疗效果的证据置信度被认为非常低,而对治疗效果的证据置信度则较低。
证据表明,在母乳喂养的婴儿中补充罗伊氏乳杆菌可减少被诊断为绞痛的婴儿的哭泣时间。但是,我们对效果估计的信心有限。